Departments of Endocrinology and Nutrition (A.G.M., S.S.P., J.C.G.) and Preventive Medicine (F.G.-G.), Clínica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain; and Department of Health Sciences (F.G.-G.), Public University of Navarra, 31008 Pamplona, Spain.
J Clin Endocrinol Metab. 2014 Mar;99(3):923-31. doi: 10.1210/jc.2013-2409. Epub 2014 Jan 1.
Thyroid dysfunction is one of the leading endocrine disorders. Previous data show that about half of the population with thyroid dysfunction remains undiagnosed.
Our objective was to estimate epidemiologic data on thyroid dysfunction in Europe.
PubMed, EMBASE, and SCOPUS databases were searched to identify studies that evaluated the prevalence and/or incidence of thyroid dysfunction in Europe published between 1975 and 2012.
Of the 541 identified abstracts examined, 178 were considered for evaluation and 17 were included. Studies were excluded if they included participants with an underlying disease or were limited by age or gender.
Results were grouped into 3 categories: 1) prevalence of undiagnosed thyroid dysfunction, 2) prevalence of thyroid dysfunction, and 3) incidence of thyroid dysfunction. Extraction was conducted independently by 2 investigators.
An empirical Bayesian random-effects model was used. The prevalence of undiagnosed thyroid dysfunction was assessed in 7 studies with a mean result of 6.71% (95% credibility interval, 6.49%-6.93%): 4.94% (4.75%-5.13%) and 1.72% (1.66%-1.88%) for undiagnosed hypothyroidism and hyperthyroidism, respectively. The prevalence of both previously diagnosed and undiagnosed thyroid dysfunction was assessed in 9 studies with a mean result of 3.82% (3.77%-3.86%): 3.05% (3.01%-3.09%) and 0.75% (0.73%-0.77%) for hypothyroidism and hyperthyroidism, respectively. The incidence rate of thyroid dysfunction was assessed in 7 studies with a mean result of 259.12 (254.39-263.9) per 100 000 per year: 226.2 (222.26-230.17) and 51 (49.23-52.88) per 100 000 per year for hypothyroidism and hyperthyroidism, respectively.
This meta-analysis provides extensive data on the prevalence and incidence of thyroid dysfunction in Europe.
甲状腺功能障碍是主要的内分泌紊乱之一。先前的数据表明，约一半的甲状腺功能障碍患者未被诊断出来。
我们的目的是评估欧洲甲状腺功能障碍的流行病学数据。
检索了 PubMed、EMBASE 和 SCOPUS 数据库，以确定 1975 年至 2012 年间发表的评估欧洲甲状腺功能障碍患病率和/或发病率的研究。
在检查的 541 份摘要中，有 178 份被认为需要评估，其中 17 份被纳入。如果研究包括患有潜在疾病的参与者或受年龄或性别限制，则将其排除在外。
结果分为 3 类：1）未确诊甲状腺功能障碍的患病率，2）甲状腺功能障碍的患病率，3）甲状腺功能障碍的发病率。提取由 2 名研究人员独立进行。
使用经验贝叶斯随机效应模型。7 项研究评估了未确诊甲状腺功能障碍的患病率，平均结果为 6.71%（95%可信度区间，6.49%-6.93%）：分别为 4.94%（4.75%-5.13%）和 1.72%（1.66%-1.88%）未确诊的甲状腺功能减退和甲状腺功能亢进症。9 项研究评估了已确诊和未确诊的甲状腺功能障碍的患病率，平均结果为 3.82%（3.77%-3.86%）：分别为 3.05%（3.01%-3.09%）和 0.75%（0.73%-0.77%）为甲状腺功能减退症和甲状腺功能亢进症。7 项研究评估了甲状腺功能障碍的发病率，平均结果为每年每 10 万人 259.12（254.39-263.9）例：每年每 10 万人 226.2（222.26-230.17）和 51（49.23-52.88）例为甲状腺功能减退症和甲状腺功能亢进症。
本荟萃分析提供了欧洲甲状腺功能障碍患病率和发病率的广泛数据。
